ATM mutations in breas cancer - a functional approach

乳腺癌中的 ATM 突变——一种功能性方法

基本信息

项目摘要

DESCRIPTION (provided by applicant): Ionizing radiation (IR) is a known breast carcinogen in both animals and humans. IR exposure generates a variety of lesions in DNA of which the most dangerous are DNA double strand breaks (DSBs). Genomic instability can result from the presence of unrepaired DSBs leading to cell death or malignant transformation. Eukaryotes have evolved efficient systems for monitoring genomic integrity and responding rapidly to their presence via cell cycle arrest, repair, and/or apoptotic mechanisms. The master regulator of the mammalian cellular DNA DSB response pathway is the protein ATM. ATM is one of several proteins in this pathway encoded by genes implicated in breast cancer susceptibility. Despite the intriguing relationship between IR, breast cancer, and these genes, there is no clear model for how this particular biochemical pathway has specific effects on breast cancer risk. We have now developed a model for the role of ATM. In this "missense-mutation" model we propose that a subset of ATM mutations act by dominant interference, reducing the intrinsic kinase activity of ATM, and/or disrupting protein complexes that include ATM. The model predicts that ATM-mediated risk for breast cancer is specific to carriers of this class of mutation and suggests that agents such as IR, which are potent inducers of ATM, may have enhanced carcinogenic effects in such individuals. In order to explore the complex relationship between ATM, radiation exposure and breast cancer, we initiated the WECARE (Women's Environment Cancer and Radiation Exposure) study in which 2100 women with either unilateral or asynchronous bilateral breast cancer are enrolled. In this collection, breast cancer risk factors have been assessed by questionnaire; both full radiation dosimetry reconstruction, and full mutation screening of the ATM gene have been carried out. Preliminary analysis of the ATM data reveals a significant increase in risk for second primary breast cancers in subjects who received radiation therapy and carry ATM missense mutations. However, mutation status determination was based only on consideration of sequence conservation-no functional confirmation of mutation status was included in the original study. In this new application, we propose to build upon these preliminary findings by directly testing the hypothesis that the incidence of contralateral breast cancer is increased among women who received radiation therapy as a treatment for their first primary breast cancer and who are carriers of specific ATM alleles which dominantly interfere with the cellular response to IR. Our studies will characterize putative ATM mutations identified in the course of WECARE screening for their functional effects on DNA damage response pathways, and then incorporate this information into the analysis of variables for the overall WECARE study.
描述(由申请方提供):电离辐射(IR)是一种已知的动物和人类乳腺癌致癌物。红外线照射会导致DNA的多种损伤,其中最危险的是DNA双链断裂(DSB)。基因组不稳定性可能是由于存在未修复的DSB导致细胞死亡或恶性转化。真核生物已经进化出有效的系统,用于监测基因组完整性并通过细胞周期停滞、修复和/或凋亡机制对其存在迅速作出反应。哺乳动物细胞DNA DSB反应途径的主要调节因子是ATM蛋白。ATM是该通路中由乳腺癌易感性相关基因编码的几种蛋白质之一。尽管IR、乳腺癌和这些基因之间存在有趣的关系,但对于这种特定的生化途径如何对乳腺癌风险产生特定影响,目前还没有明确的模型。我们现在已经为ATM的作用开发了一个模型。在这个“错义突变”模型中,我们提出ATM突变的一个子集通过显性干扰起作用,降低ATM的内在激酶活性,和/或破坏包括ATM的蛋白质复合物。该模型预测,ATM介导的乳腺癌风险是特定于这类突变的携带者,并表明,代理人,如IR,这是ATM的有效诱导剂,可能有增强的致癌作用,在这样的个人。为了探讨ATM,辐射暴露和乳腺癌之间的复杂关系,我们发起了WECARE(妇女的环境癌症和辐射暴露)的研究,其中2100名妇女无论是单侧或异步双侧乳腺癌。在这个集合中,乳腺癌的危险因素进行了评估问卷调查,都进行了全面的辐射剂量重建,和ATM基因的突变筛查。对ATM数据的初步分析显示,接受放射治疗并携带ATM错义突变的受试者发生第二原发性乳腺癌的风险显著增加。然而,突变状态的确定仅基于对序列保守性的考虑-在原始研究中未包括突变状态的功能确认。在这个新的应用程序中,我们建议在这些初步发现的基础上,通过直接检验以下假设:在接受放射治疗作为首次原发性乳腺癌治疗的妇女中,对侧乳腺癌的发病率增加,这些妇女是特异性ATM等位基因的携带者,这些等位基因主要干扰细胞对IR的反应。WECARE筛选它们对DNA损伤反应途径的功能影响,然后将这些信息纳入整个WECARE研究的变量分析中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patrick Concannon其他文献

Patrick Concannon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Patrick Concannon', 18)}}的其他基金

Novel DNA damage response gene from genomic screening
来自基因组筛选的新型 DNA 损伤反应基因
  • 批准号:
    9324064
  • 财政年份:
    2016
  • 资助金额:
    $ 48.97万
  • 项目类别:
Novel DNA damage response gene from genomic screening
来自基因组筛选的新型 DNA 损伤反应基因
  • 批准号:
    9158855
  • 财政年份:
    2016
  • 资助金额:
    $ 48.97万
  • 项目类别:
Novel T1D risk variants from genomic analyses in high risk families
高风险家庭基因组分析中发现的新型 T1D 风险变异
  • 批准号:
    9100744
  • 财政年份:
    2015
  • 资助金额:
    $ 48.97万
  • 项目类别:
Novel T1D risk variants from genomic analyses in high risk families
高风险家庭基因组分析中发现的新型 T1D 风险变异
  • 批准号:
    8955744
  • 财政年份:
    2015
  • 资助金额:
    $ 48.97万
  • 项目类别:
Identification of radiation sensitivity alleles by whole exome sequencing
通过全外显子组测序鉴定辐射敏感性等位基因
  • 批准号:
    8181128
  • 财政年份:
    2011
  • 资助金额:
    $ 48.97万
  • 项目类别:
Identification of radiation sensitivity alleles by whole exome sequencing
通过全外显子组测序鉴定辐射敏感性等位基因
  • 批准号:
    8661941
  • 财政年份:
    2011
  • 资助金额:
    $ 48.97万
  • 项目类别:
Identification of radiation sensitivity alleles by whole exome sequencing
通过全外显子组测序鉴定辐射敏感性等位基因
  • 批准号:
    8323119
  • 财政年份:
    2011
  • 资助金额:
    $ 48.97万
  • 项目类别:
ATM mutations in breas cancer - a functional approach
乳腺癌中的 ATM 突变——一种功能性方法
  • 批准号:
    7286423
  • 财政年份:
    2005
  • 资助金额:
    $ 48.97万
  • 项目类别:
ATM mutations in breas cancer - a functional approach
乳腺癌中的 ATM 突变——一种功能性方法
  • 批准号:
    7500539
  • 财政年份:
    2005
  • 资助金额:
    $ 48.97万
  • 项目类别:
ATM mutations in breas cancer - a functional approach
乳腺癌中的 ATM 突变——一种功能性方法
  • 批准号:
    7104378
  • 财政年份:
    2005
  • 资助金额:
    $ 48.97万
  • 项目类别:

相似海外基金

The mechanism of CELF1 upregulation and its role in the pathogenesis of Myotonic Dystrophy Type 1
CELF1上调机制及其在强直性肌营养不良1型发病机制中的作用
  • 批准号:
    10752274
  • 财政年份:
    2024
  • 资助金额:
    $ 48.97万
  • 项目类别:
Role of intestinal serotonin transporter in post traumatic stress disorder
肠道血清素转运蛋白在创伤后应激障碍中的作用
  • 批准号:
    10590033
  • 财政年份:
    2024
  • 资助金额:
    $ 48.97万
  • 项目类别:
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 48.97万
  • 项目类别:
Individual Predoctoral Fellowship
个人博士前奖学金
  • 批准号:
    10752036
  • 财政年份:
    2024
  • 资助金额:
    $ 48.97万
  • 项目类别:
Drivers and consequences of introgression in evolution
进化中基因渗入的驱动因素和后果
  • 批准号:
    10552299
  • 财政年份:
    2023
  • 资助金额:
    $ 48.97万
  • 项目类别:
Orthogonal CRISPR GEMMs
正交 CRISPR GEMM
  • 批准号:
    10639698
  • 财政年份:
    2023
  • 资助金额:
    $ 48.97万
  • 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
  • 批准号:
    10637251
  • 财政年份:
    2023
  • 资助金额:
    $ 48.97万
  • 项目类别:
Modulation of NOD Strain Diabetes by ENU-Induced Mutations
ENU 诱导突变对 NOD 菌株糖尿病的调节
  • 批准号:
    10642549
  • 财政年份:
    2023
  • 资助金额:
    $ 48.97万
  • 项目类别:
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
靶向端粒酶逆转录酶 (TERT) 的突变启动子
  • 批准号:
    10677899
  • 财政年份:
    2023
  • 资助金额:
    $ 48.97万
  • 项目类别:
Characterizing Entorhinal Cortex Circuit Dysfunction in an APOE Mouse Model of Chemotherapy-Induced Cognitive Impairment
化疗引起认知障碍的 APOE 小鼠模型中内嗅皮层回路功能障碍的特征
  • 批准号:
    10677984
  • 财政年份:
    2023
  • 资助金额:
    $ 48.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了